Ionis Pharmaceuticals (IONS) revenue breakdown
By segment, Ionis is the largest at 80% of fiscal 2020 revenue; Akcea Therapeutics grew fastest, 53% a year over 2 years.
By product, Collaborative Agreement Revenue is the largest at 49% of fiscal 2025 revenue; WAINUA Royalties grew fastest, 143% a year over 1 years.
Revenue by segment
Fiscal years, as Ionis Pharmaceuticals reports them in its 10-K filings; fiscal 2020 total $775M.
| Segments | 2018 | 2019 | 2020 | Share |
|---|---|---|---|---|
| Ionis | $642M | $859M | $623M | 80% |
| Akcea Therapeutics | $65M | $489M | $152M | 20% |
Revenue by product
Fiscal years, as Ionis Pharmaceuticals reports them in its 10-K filings; fiscal 2025 total $944M.
| Products | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Share |
|---|---|---|---|---|---|---|---|---|---|
| Collaborative Agreement Revenue | $345M | $770M | $365M | $468M | $207M | $353M | $333M | $466M | 49% |
| SPINRAZA Royalties | $238M | $293M | $287M | $268M | $242M | $240M | $216M | $212M | 22% |
| TRYNGOLZA Sales | — | — | — | — | — | — | — | $108M | 11% |
| WAINUA Royalties | — | — | — | — | — | — | $20M | $49M | 5% |
| WAINUA Joint Development Revenue | — | — | — | — | $77M | $126M | $79M | $42M | 4% |
| Other Commercial Revenue | — | — | — | — | — | $36M | $36M | $35M | 4% |
| Other Royalties | — | — | — | — | — | $32M | $21M | $24M | 3% |
| DAWNZERA Sales | — | — | — | — | — | — | — | $8M | 1% |
| Other Revenue | $15M | $17M | $8M | $19M | $31M | — | — | — | — |
| TEGSEDI and WAYLIVRA Revenue, Net | $2M | $42M | $70M | $56M | $30M | — | — | — | — |
Every line, every quarterThe deep dive has fifteen-plus years of statements, quarterly results, charts and valuation models for IONS.
Open IONS in InvestinglyQuestions
Where does Ionis Pharmaceuticals make its money?
In fiscal 2020, by segment: Ionis $623M, Akcea Therapeutics $152M.
From Ionis Pharmaceuticals's annual reports filed with the SEC (XBRL data), standardised by Investingly. Information only, not investment advice.